|

Clinical Response and Toxicity of Hypo-fractionated Chemoradiotherapy in Cervix Cancer

RECRUITINGPhase 2Sponsored by Tehran University of Medical Sciences
Actively Recruiting
PhasePhase 2
SponsorTehran University of Medical Sciences
Started2021-04-01
Est. completion2023-03
Eligibility
Age18 Years – 85 Years
SexFEMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT04831437

Summary

Uterine cervix cancer can be treated definitively with concurrent chemoradiation (external beam radiotherapy and chemotherapy) followed by high dose rate brachytherapy. Treatment duration can be shortened by increasing the dose per fraction of treatment which can reduce costs and patient exposure. The aim of our study is to determine the non-inferiority of hypofractionated radiotherapy compared with conventional treatment.

Eligibility

Age: 18 Years – 85 YearsSex: FEMALEHealthy volunteers accepted
Inclusion Criteria:

* Pathology of squamous cell carcinoma (SCC), adenocarcinoma, adenosquamous carcinoma of uterine cervix- International Federation of Gynecology and Obstetrics (FIGO) stage IB, IIA, IIB, IIIA, IIIB (due to hydronephrosis without creatinine clearance compromise), IIIC1 (if less than 3 lymph nodes with size less than 3cm, and without involvement of common iliac chain)- Patient eligible for definitive chemoradiotherapy followed by brachytherapy

Exclusion Criteria:

* Creatinine clearance less than 30ml/min, any histology other than the above, requirement of paraaortic lymph node irradiation, inflammatory bowel disease, connective tissue disorders, previous pelvic radiotherapy, FIGO stage IA or IV, Eastern Cooperative Oncology Group (ECOG) performance status greater than 2, History of previous hysterectomy

Conditions2

CancerCervix Uteri Cancer

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.